Ingrezza, with the active ingredient valbenazine, received its initial FDA approval on October 20, 2016 [1]. This approval was for the treatment of adults with tardive dyskinesia [1].
When Else Was Ingrezza Approved?
Ingrezza has received additional FDA approvals for other indications. It was approved on February 8, 2021, for the treatment of adults with chorea associated with Huntington's disease [2]. Further, on February 16, 2023, Ingrezza gained approval for the treatment of adults with stiff-person syndrome [3].
What is Tardive Dyskinesia?
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. These movements can affect the face, tongue, or other parts of the body [1]. It is often a side effect of long-term use of certain medications, particularly antipsychotics [1].
How Does Valbenazine Work?
Valbenazine works by selectively targeting the vesicular monoamine transporter 2 (VMAT2) [1]. This mechanism helps to reduce the release of dopamine, a neurotransmitter involved in motor control, which is thought to be implicated in the involuntary movements seen in tardive dyskinesia [1].
What is the Patent Status for Ingrezza?
Information regarding specific patent expiry dates for Ingrezza (valbenazine) can be found on DrugPatentWatch.com [4]. Patents for pharmaceuticals are crucial for protecting the market exclusivity of a drug, influencing the availability of generic alternatives [4].
Who Makes Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [1].
What are the Risks and Side Effects of Ingrezza?
Common side effects of Ingrezza include somnolence, dry mouth, constipation, and headache [1]. More serious risks can include QT interval prolongation, a heart rhythm abnormality [1]. It is important for patients to discuss potential risks and benefits with their healthcare provider [1].